메뉴 건너뛰기




Volumn 22, Issue 3, 2004, Pages 315-322

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

Author keywords

Cyclin; Cyclin dependent kinase; Flavopiridol; Melanoma

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; BISMUTH SALICYLATE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; LOPERAMIDE; ONDANSETRON;

EID: 3542996265     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000026258.02846.1c     Document Type: Article
Times cited : (88)

References (28)
  • 2
    • 0012415819 scopus 로고    scopus 로고
    • Toronto, Canada
    • National Cancer Institute of Canada: Canadian Cancer Statistics, Toronto, Canada, 2002. http://www.ncic.cancer.ca
    • (2002) Canadian Cancer Statistics
  • 4
    • 0025058101 scopus 로고
    • Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit
    • Lakhani S, Selby P, Bliss JM, Perren TJ, Gore ME, McElwain TJ: Chemotherapy for malignant melanoma: Combinations and high doses produce more responses without survival benefit. Br J Cancer 61: 330-334, 1990
    • (1990) Br J Cancer , vol.61 , pp. 330-334
    • Lakhani, S.1    Selby, P.2    Bliss, J.M.3    Perren, T.J.4    Gore, M.E.5    McElwain, T.J.6
  • 5
    • 0002262637 scopus 로고
    • Melanoma
    • De Vita VT, Hellman S, Rosenberg SA (eds) Lippincott. Philadephia
    • Kirkwood JM: Melanoma. In: De Vita VT, Hellman S, Rosenberg SA (eds) Biologic Therapy of Cancer. Lippincott. Philadephia, 1995, pp 388-411
    • (1995) Biologic Therapy of Cancer , pp. 388-411
    • Kirkwood, J.M.1
  • 6
    • 0031805726 scopus 로고    scopus 로고
    • Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
    • Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 16: 1752-1759, 1998
    • (1998) J Clin Oncol , vol.16 , pp. 1752-1759
    • Legha, S.S.1    Ring, S.2    Eton, O.3    Bedikian, A.4    Buzaid, A.C.5    Plager, C.6    Papadopoulos, N.7
  • 7
    • 0032772629 scopus 로고    scopus 로고
    • Expression of cell cycle regulators in human cutaneous malignant melanoma
    • Tang L, Li G, Tron VA, Trotter MJ, Ho VC: Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res 9: 148-154, 1999
    • (1999) Melanoma Res , vol.9 , pp. 148-154
    • Tang, L.1    Li, G.2    Tron, V.A.3    Trotter, M.J.4    Ho, V.C.5
  • 9
    • 0029665778 scopus 로고    scopus 로고
    • Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells
    • Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK)2 and CDK4 in human breast carcinoma cells. Cancer Res 56: 2973-2978, 1996
    • (1996) Cancer Res , vol.56 , pp. 2973-2978
    • Carlson, B.A.1    Dubay, M.M.2    Sausville, E.A.3    Brizuela, L.4    Worland, P.J.5
  • 11
    • 0029904810 scopus 로고    scopus 로고
    • Flavopiridol. A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells
    • Bible KC, Kaufmann SH: Flavopiridol. A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56: 4856-4861, 1996
    • (1996) Cancer Res , vol.56 , pp. 4856-4861
    • Bible, K.C.1    Kaufmann, S.H.2
  • 17
    • 0033955395 scopus 로고    scopus 로고
    • Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study
    • Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18: 371-375, 2000
    • (2000) J Clin Oncol , vol.18 , pp. 371-375
    • Stadler, W.M.1    Vogelzang, N.J.2    Amato, R.3    Sosman, J.4    Taber, D.5    Liebowitz, D.6    Vokes, E.E.7
  • 23
    • 0034294533 scopus 로고    scopus 로고
    • Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol
    • Li Y, Chinni SR, Senderowicz AM, Sarkar FH: Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol. Int J Oncol 17: 755-759, 2000
    • (2000) Int J Oncol , vol.17 , pp. 755-759
    • Li, Y.1    Chinni, S.R.2    Senderowicz, A.M.3    Sarkar, F.H.4
  • 25
    • 0034752936 scopus 로고    scopus 로고
    • Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol
    • Smith V, Raynaud F, Workman P, Kelland LR: Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Molecular Pharmacology 60: 885-893, 2001
    • (2001) Molecular Pharmacology , vol.60 , pp. 885-893
    • Smith, V.1    Raynaud, F.2    Workman, P.3    Kelland, L.R.4
  • 26
    • 0035120249 scopus 로고    scopus 로고
    • Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol
    • Kahn ME, Senderowicz A, Sausville EA, Barrett KE: Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clinical Cancer Research 7: 343-349, 2001
    • (2001) Clinical Cancer Research , vol.7 , pp. 343-349
    • Kahn, M.E.1    Senderowicz, A.2    Sausville, E.A.3    Barrett, K.E.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.